drugset / Trial / NCT01033097
Safety and Efficacy of DNK333 in Atopic Dermatitis Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will assess the safety and efficacy of DNK333 in patients with atopic dermatitis suffering from pruritus, who require systemic treatment of the disease.
Timeline
- Start
- 2009-11
- Primary completion
- 2011-07
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Betamethasone | Other / unclassified | 4 mg | Oral |
| Subject | DNK333 | Small molecule | 1 mg | Oral |
| Subject | DNK333 | Small molecule | 5 mg | Oral |
| Subject | DNK333 | Small molecule | 25 mg | Oral |
| Subject | DNK333 | Small molecule | 100 mg | Oral |